UBS Group AG Has $2.57 Million Stock Holdings in Anteris Technologies Global Corp. $AVR

UBS Group AG boosted its position in shares of Anteris Technologies Global Corp. (NASDAQ:AVR) by 133.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 515,725 shares of the company’s stock after buying an additional 294,695 shares during the quarter. UBS Group AG’s holdings in Anteris Technologies Global were worth $2,573,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. L1 Capital Pty Ltd lifted its holdings in Anteris Technologies Global by 143.2% during the 3rd quarter. L1 Capital Pty Ltd now owns 6,838,136 shares of the company’s stock worth $30,772,000 after buying an additional 4,026,136 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Anteris Technologies Global by 13.3% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,918,666 shares of the company’s stock valued at $8,634,000 after purchasing an additional 225,000 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Anteris Technologies Global by 32.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,417,627 shares of the company’s stock valued at $6,379,000 after purchasing an additional 349,299 shares during the period. Vanguard Group Inc. lifted its stake in shares of Anteris Technologies Global by 85.1% in the 3rd quarter. Vanguard Group Inc. now owns 745,560 shares of the company’s stock valued at $3,355,000 after purchasing an additional 342,711 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Anteris Technologies Global by 154.3% in the 2nd quarter. Geode Capital Management LLC now owns 420,427 shares of the company’s stock valued at $1,593,000 after purchasing an additional 255,088 shares during the period.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AVR. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price target on shares of Anteris Technologies Global in a research note on Friday, March 27th. Wells Fargo & Company began coverage on Anteris Technologies Global in a research note on Wednesday, March 11th. They issued an “overweight” rating and a $16.00 price target on the stock. Barclays increased their price target on Anteris Technologies Global from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, Wall Street Zen raised Anteris Technologies Global from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Anteris Technologies Global has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Anteris Technologies Global Trading Down 5.6%

Shares of Anteris Technologies Global stock opened at $9.08 on Wednesday. The company has a market capitalization of $883.85 million, a PE ratio of -4.07 and a beta of 1.32. Anteris Technologies Global Corp. has a 12 month low of $2.85 and a 12 month high of $9.79. The stock’s fifty day simple moving average is $6.29 and its 200 day simple moving average is $5.58.

Anteris Technologies Global (NASDAQ:AVR) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.01). The business had revenue of $0.49 million for the quarter, compared to analyst estimates of $0.77 million. Anteris Technologies Global had a negative return on equity of 124.76% and a negative net margin of 5,148.78%.During the same period in the previous year, the business posted ($0.61) EPS. Analysts predict that Anteris Technologies Global Corp. will post -1.14 EPS for the current fiscal year.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.